Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital is ranked No. 4 nationally for Cardiology, Heart and Vascular Surgery, and Fuster Heart Hospital at Mount Sinai Morningside and Mount Sinai West are ranked No. 18 nationally, by U.S. News & World Report for 2024-25. Fuster Heart Hospital at The Mount Sinai Hospital is ranked No. 1 in New York and No. 6 globally by Newsweek’s “World’s Best Specialized Hospitals” in 2025 for both Cardiology and Cardiac Surgery.
I am proud to share some of the year’s highlights for our dedicated physicians and scientists:
Valentin Fuster, MD, PhD, the President and founder of Fuster Heart Hospital, launched the PRECAD (Prevent Coronary Artery Disease) trial to explore strategies to prevent the progression of atherosclerotic plaque in a young population by strict control of risk factors.
David H. Adams, MD, was a co-principal investigator in the TRILUMINATE pivotal trial, which helped prove the safety and efficacy of tricuspid transcatheter edge-to-edge repair (T-TEER). Gilbert H.L. Tang, MD, led a team performing one of the first T-TEER procedures in the United States, and Mount Sinai is now among the highest-volume centers for mitral and T-TEER procedures in the nation.
Vivek Y. Reddy, MD, a pioneer in pulsed field ablation (PFA), led the international MANIFEST-17K trial, which found that PFA is safe for treating patients with common types of atrial fibrillation. In a late-breaking presentation, he reported that the Advantage AF trial found favorable outcomes in safety, efficiency, and effectiveness.
Under the leadership of Samin K. Sharma, MD, and Annapoorna S. Kini, MD, the Cardiac Catheterization Laboratory at The Mount Sinai Hospital continued to excel in safety and volume. It continued to provide guidance to the field, with publications including two papers by Dr. Kini and Keisuke Yasumura, MD, that describe a new approach for managing coronary calcium and calcified nodules with an evidence-based algorithm guided by optical coherence tomography imaging.
“I wish you the best in your own practice and invite you to peruse this report, which highlights our dedicated work in cardiology, cardiac surgery, and research.”
Roxanna Mehran, MD, was co-principal investigator of the groundbreaking SMART trial, which for the first time provided female-specific data to inform the treatment of women with aortic stenosis, who are at greatest risk for hemodynamic valve dysfunction after transcatheter aortic-valve replacement due to their small aortic annulus. This year Dr. Mehran takes office as Vice President of the American College of Cardiology.
We continue to advance cardiology in both fundamental and translational research. The Cardiovascular Research Institute, led by Filip K. Swirski, PhD, made discoveries in lifestyle and prevention, systems physiology and bioengineering, and genetic medicine. A breakthrough study by Jason C. Kovacic, MD, PhD, and Jeffrey W. Olin, DO, identified a key driver of fibromuscular dysplasia, a poorly understood disorder that affects up to 5 percent of women. A study led by Cameron McAlpine, PhD, and Dr. Swirski was the first to demonstrate how the heart and brain communicate with each other through the immune system to promote sleep and recovery after myocardial infarction.
Robert S. Rosenson, MD, led a global clinical trial that found that a small interfering RNA therapy significantly reduced the levels of cholesterol and triglycerides in patients with mixed hyperlipidemia. And the ULTIMATE-DAPT study, led by Gregg Stone, MD, found that withdrawing aspirin one month after percutaneous coronary intervention in high-risk heart patients and keeping them on ticagrelor alone safely improves outcomes and reduces major bleeding by more than half when compared to patients taking the current standard of care.
Icilma Fergus, MD—a leader in cardiovascular health equity and community outreach—is the site principal investigator in the nation’s first clinical trial to determine whether coronary artery bypass graft or PCI is most effective in improving survival and quality of life of women and Black and Hispanic populations. Dr. Stone is a national co-principal investigator of this study.
Our internationally recognized Cardiovascular Training Program attracts exceptional, diverse candidates from the leading institutions in the country, who become future leaders in cardiovascular medicine.
I wish you the best in your own practice and invite you to peruse this report, which highlights the dedicated work of Mount Sinai Fuster Heart Hospital in cardiology, cardiac surgery, and research.
Deepak L. Bhatt, MD, MPH, MBA
Director of Mount Sinai Fuster Heart Hospital